Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease.

Deleye, Steven; Waldron, Ann-Marie; Verhaeghe, Jeroen; Bottelbergs, Astrid; Wyffels, Leonie; Van Broeck, Bianca; Langlois, Xavier; Schmidt, Mark et al. · J Nucl Med · 2017

basic_science · Level V

Where this comes from

Abstract

In this study, we investigated the effects of chronic administration of an inhibitor of the β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) on Alzheimer-related pathology by multitracer PET imaging in transgenic APPPS1-21 (TG) mice. <b>Methods:</b> Wild-type (WT) and TG mice received vehicle or BACE inhibitor (60 mg/kg) starting at 7 wk of age. Outcome measures of brain metabolism, neuroinflammation, and amyloid-β pathology were obtained through small-animal PET imaging with <sup>18</sup>F-FDG, <sup>18</sup>F-peripheral benzodiazepine receptor (<sup>18</sup>F-PBR), and <sup>18</sup>F-florbetapir (<sup>18</sup>F-AV45), respectively. Baseline scans were acquired at 6-7 wk of age and follow-up scans at 4, 7, and 12 mo. <sup>18</sup>F-AV45 uptake was measured at 8 and 13 mo of age. After the final scans, histologic measures of amyloid-β (4G8), microglia (ionized calcium binding adaptor molecule 1), astrocytes (glial fibrillary acidic protein), and neuronal nuclei were performed. <b>Results:</b> TG mice demonstrated significant age-associated increases in <sup>18</sup>F-AV45 uptake. An effect of treatment was observed in the cortex (<i>P</i> = 0.0014), hippocampus (<i>P</i> = 0.0005), and thalamus (<i>P</i> < 0.0001). Histology confirmed reduction of amyloid-β pathology in TG-BACE mice. Regardless of treatment, TG mice demonstrated significantly lower <sup>18</sup>F-FDG uptake than WT mice in the thalamus (<i>P</i> = 0.0004) and hippocampus (<i>P</i> = 0.0332). Neuronal nucleus staining was lower in both TG groups in the thalamus and cortex. <sup>18</sup>F-PBR111 detected a significant age-related increase in TG mice (<i>P</i> < 0.0001) but did not detect the treatment-induced reduction in activated microglia as demonstrated by histology. <b>Conclusion:</b> Although <sup>18</sup>F-FDG, <sup>18</sup>F-PBR111, and <sup>18</sup>F-AV45 all detected pathologic alterations between TG and WT mice, only <sup>18</sup>F-AV45 could detect an effect of BACE inhibitor treatment. However, changes in WT binding of <sup>18</sup>F-AV45 undermine the specificity of this effect.

Medical subject headings